United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...
Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...
BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...
It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...
Investor's Business Daily on MSN4d
Investing Action Plan: Anduril Industries, United Therapeutics, Barstool In MiamiThe stock market is waiting on a follow through day. Miami's eMerge Americas conference may provide some surprise energy for ...
StockStory.org on MSN27d
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With ExpectationsBiotechnology company United Therapeutics (NASDAQ:UTHR) in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its ...
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback